Straits Times Index
3,306.40 -15.68 (-0.47%) Nikkei
39,134.79 +96.63 (+0.25%) Hang Seng
18,193.90 -173.05 (-0.94%) FTSE 100
8,239.10 +10.62 (+0.13%) Bitcoin USD
67,513.33 -1,896.12 (-2.73%) CMC Crypto 200
1,398.44 -43.20 (-3.00%)
BIIB Oct 2024 170.000 put
| Previous close | 1.3400 |
| Open | 1.5000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 170.00 |
| Expiry date | 2024-10-18 |
| Day's range | 1.3400 - 1.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Yahoo FinanceFDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
An FDA panel voted unanimously to support Eli Lilly's Alzheimer's drug for use in adults 60-85 years old.
ZacksBiogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.
GlobeNewswireFDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. A Prescription Drug Us
